Stephen Pasternak, MD, PhD, FRCPC, Robarts Research Institute, Western University, London, Ontario, Canada, outlines advances in Alzheimer’s disease biomarkers. Although several studies investigating CSF and imaging biomarkers, such as amyloid-ß (Aß) and tau, have shown interesting results, those haven’t been good enough to move them into clinical practice. Meanwhile, blood tests used to diagnose pre-symptomatic patients have recently shown promising results. The field is also witnessing advances in the development and clinical use of monoclonal antibodies targeting Aß that could transform the disease treatment landscape in the following years. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.
